Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_assertion type Assertion NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_head.
- NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_assertion description "[Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukemias (FLT3 and KIT).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_provenance.
- NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_assertion evidence source_evidence_literature NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_provenance.
- NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_assertion SIO_000772 23497317 NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_provenance.
- NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_assertion wasDerivedFrom befree-20140225 NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_provenance.
- NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_assertion wasGeneratedBy ECO_0000203 NP709539.RAkVKEP0jvL-IqPxMVtyEcK-IjmA7WVKa4QVLh8J2cT1Y130_provenance.